Pharmaceutical Technology6 天
Nadunolimab by Cantargia for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Nadunolimab is under clinical development by Cantargia and currently in Phase II for Squamous Non-Small Cell Lung Cancer.
Verywell Health on MSN1 年
The Ins and Outs of Stage 1 Lung Cancer Treatment, Symptoms, and Diagnosis
Medically reviewed by Gagandeep Brar, MD Lung cancer is one of the most common cancers. Stage 1 lung cancer is defined by ...
Pharmaceutical Technology6 天
Envafolimab by Alphamab Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.
Cure Today13 天
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
2minutemedicine.com6 天
AstraZeneca’s Imfinzi shows positive results in phase 3 trial for treatment of limited ...
Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...
Science Daily1 个月
DNA secreted by tumor cell extracellular vesicles prompts anti-metastatic immune response
The discovery improves the scientific understanding of cancer progression and ... in the EV-DNA to organize immune cell clusters that resist liver metastases. "This is a tumor suppressor mechanism ...
WebMD28 天
FDA Approves Drug for Aggressive Small-Cell Lung Cancer
The FDA has approved the drug durvalumab for adults with limited-stage small-cell ... cancer cells more effectively. Imfinzi was first approved by the FDA in 2017 for use against various lung ...